Covariation of copy number located at 16q22.1: Νew evidence in mammary ductal carcinoma

Sun,Qian; Yang,Yan-Mei; Yu,Shi-Hui; Zhang,You-Xue; He,Xiao-Guang; Sun,Shan-Shan; Liang,Xiao-Shuan; Pang,Da

doi:10.3892/or.2012.2050

Covariation of copy number located at 16q22.1: Νew evidence in mammary ductal carcinoma

Authors:
- Qian Sun
- Yan-Mei Yang
- Shi-Hui Yu
- You-Xue Zhang
- Xiao-Guang He
- Shan-Shan Sun
- Xiao-Shuan Liang
- Da Pang
View Affiliations

Affiliations: Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin 150081, P.R. China, Cancer Research Institute, Harbin Medical University, Harbin 150081, P.R. China, Department of Pathology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA
Published online on: September 20, 2012 https://doi.org/10.3892/or.2012.2050
Pages: 2156-2162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Copy number variation (CNV) is crucial for gene regulation in humans. A number of studies have revealed that CNV contributes to the initiation and progression of cancer. In this study, we analysed four breast cancer cell lines and six fresh frozen tissues from patients to evaluate the CNV present in the genome using microarray-based comparative genomic hybridization (aCGH). Six genes located at 16q22.1 were analysed by real-time PCR. The real-time PCR analysis revealed that the loss of CDH1/E2F4 may be associated with worse clinical and pathological findings. Interestingly, covariation of CDH1, CDH3, CTCF and E2F4 was found to be associated with triple negative breast cancer and HER-2 receptor status. In conclusion, our study supports the idea that CNV at 16q22.1 in breast cancer is a frequent event; furthermore, it reveals the covariation of CDH1, CDH3, CTCF and E2F4. The role of the covariation is more complex than a simple additive effect of these four separate genes, which may provide a novel target for breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Rajski M, Vogel B, Baty F, Rochlitz C and Buess M: Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One. 7:e297432012. View Article : Google Scholar : PubMed/NCBI
3	Nemes S, Parris TZ, Danielsson A, et al: Segmented regression, a versatile tool to analyze mRNA levels in relation to DNA copy number aberrations. Genes Chromosomes Cancer. 51:77–82. 2012. View Article : Google Scholar : PubMed/NCBI
4	Iafrate AJ, Feuk L, Rivera MN, et al: Detection of large-scale variation in the human genome. Nat Genet. 36:949–951. 2004. View Article : Google Scholar : PubMed/NCBI
5	Sebat J, Lakshmi B, Troge J, et al: Large-scale copy number polymorphism in the human genome. Science. 305:525–528. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kuiper RP, Ligtenberg MJ, Hoogerbrugge N and Geurts van Kessel A: Germline copy number variation and cancer risk. Curr Opin Genet Dev. 20:282–289. 2010. View Article : Google Scholar
7	Staaf J, Jonsson G, Ringner M, Baldetorp B and Borg A: Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 13:R1292011. View Article : Google Scholar : PubMed/NCBI
8	Bunyan DJ, Eccles DM, Sillibourne J, et al: Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 91:1155–1159. 2004. View Article : Google Scholar
9	Hungermann D, Schmidt H, Natrajan R, et al: Influence of whole arm loss of chromosome 16q on gene expression patterns in estrogen receptor-positive, invasive breast cancer. J Pathol. 224:517–528. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y and Iwase H: Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer. BMC Cancer. 8:2622008. View Article : Google Scholar : PubMed/NCBI
11	Cleton-Jansen AM: E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 4:5–8. 2002. View Article : Google Scholar : PubMed/NCBI
12	Cleton-Jansen AM, Callen DF, Seshadri R, et al: Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res. 61:1171–1177. 2001.PubMed/NCBI
13	Dorion-Bonnet F, Mautalen S, Hostein I and Longy M: Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers. Genes Chromosomes Cancer. 14:171–181. 1995. View Article : Google Scholar : PubMed/NCBI
14	Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P and Humar B: Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J Pathol. 218:265–272. 2009. View Article : Google Scholar : PubMed/NCBI
15	Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA and Rogatto SR: CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer. 6:482006. View Article : Google Scholar : PubMed/NCBI
16	Berx G, Cleton-Jansen AM, Strumane K, et al: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 13:1919–1925. 1996.PubMed/NCBI
17	Berx G, Cleton-Jansen AM, Nollet F, et al: E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14:6107–6115. 1995.PubMed/NCBI
18	Kanai Y, Oda T, Tsuda H, Ochiai A and Hirohashi S: Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res. 85:1035–1039. 1994. View Article : Google Scholar : PubMed/NCBI
19	Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F and Schmitt FC: P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 11:5869–5877. 2005. View Article : Google Scholar : PubMed/NCBI
20	Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D and Palacios J: The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol. 14:650–654. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kremmidiotis G, Baker E, Crawford J, Eyre HJ, Nahmias J and Callen DF: Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics. 49:467–471. 1998. View Article : Google Scholar : PubMed/NCBI
22	Ho GH, Calvano JE, Bisogna M and Van Zee KJ: Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas. Breast Cancer Res Treat. 69:115–122. 2001. View Article : Google Scholar : PubMed/NCBI
23	Filippova GN, Lindblom A, Meincke LJ, et al: A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer. 22:26–36. 1998. View Article : Google Scholar
24	Matsutani N, Yokozaki H, Tahara E, et al: Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol. 19:507–512. 2001.PubMed/NCBI
25	Broccoli D, Chong L, Oelmann S, et al: Comparison of the human and mouse genes encoding the telomeric protein, TRF1: chromosomal localization, expression and conserved protein domains. Hum Mol Genet. 6:69–76. 1997. View Article : Google Scholar : PubMed/NCBI
26	Tsuji K, Kawauchi S, Saito S, et al: Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer. 10:152010. View Article : Google Scholar
27	Hazan RB, Qiao R, Keren R, Badano I and Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci. 1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
28	Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI
29	Birchmeier W and Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1198:11–26. 1994.PubMed/NCBI
30	Parker BS, Argani P, Cook BP, et al: Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 64:7857–7866. 2004. View Article : Google Scholar : PubMed/NCBI
31	Zanetta L, Corada M, Grazia Lampugnani M, et al: Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications. Thromb Haemost. 93:1041–1046. 2005.PubMed/NCBI
32	Vostrov AA and Quitschke WW: The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem. 272:33353–33359. 1997. View Article : Google Scholar : PubMed/NCBI
33	Filippova GN, Fagerlie S, Klenova EM, et al: An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol. 16:2802–2813. 1996.
34	Burcin M, Arnold R, Lutz M, et al: Negative protein 1, which is required for function of the chicken lysozyme gene silencer in conjunction with hormone receptors, is identical to the multivalent zinc finger repressor CTCF. Mol Cell Biol. 17:1281–1288. 1997.PubMed/NCBI
35	Filippova GN, Qi CF, Ulmer JE, et al: Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res. 62:48–52. 2002.PubMed/NCBI
36	Kanduri C, Pant V, Loukinov D, et al: Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol. 10:853–856. 2000. View Article : Google Scholar : PubMed/NCBI
37	Rasko JE, Klenova EM, Leon J, et al: Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res. 61:6002–6007. 2001.PubMed/NCBI
38	Ikeda MA, Jakoi L and Nevins JR: A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci USA. 93:3215–3220. 1996. View Article : Google Scholar : PubMed/NCBI
39	Yamada K, Yagihashi A, Yamada M, et al: Decreased gene expression for telomeric-repeat binding factors and TIN2 in malignant hematopoietic cells. Anticancer Res. 22:1315–1320. 2002.PubMed/NCBI
40	Karlseder J, Broccoli D, Dai Y, Hardy S and de Lange T: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1321–1325. 1999. View Article : Google Scholar : PubMed/NCBI
41	Yamada M, Tsuji N, Nakamura M, et al: Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res. 22:3303–3307. 2002.PubMed/NCBI
42	Coleman WB and Tsongalis GJ: Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem. 41:644–657. 1995.PubMed/NCBI
43	Cavenee WK: Tumor progression stage: specific losses of heterozygosity. Princess Takamatsu Symp. 20:33–42. 1989.PubMed/NCBI